Cargando…
ROS1-rearranged putative lung adenocarcinoma presenting as carcinoma of unknown primary site: a case report
Carcinoma of unknown primary site (CUP) is diagnosed only in 2-9% of all cancer cases. Adenocarcinomas account for approximately 60% of CUP, and some of these are putative lung adenocarcinomas. The frequency of driver oncogene positivity in the putative lung adenocarcinomas is unknown, and the effic...
Autores principales: | Taniwaki, Masaya, Yamasaki, Masahiro, Kawata, Koto, Kawamoto, Kazuma, Funaishi, Kunihiko, Matsumoto, Yu, Matsumoto, Naoko, Ohashi, Nobuyuki, Hattori, Noboru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219662/ https://www.ncbi.nlm.nih.gov/pubmed/30443294 http://dx.doi.org/10.18632/oncotarget.26233 |
Ejemplares similares
-
Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report
por: Yamasaki, Masahiro, et al.
Publicado: (2019) -
Nivolumab therapy for lung cancer with tracheo-parenchymal fistula: A case report
por: Yamasaki, Masahiro, et al.
Publicado: (2018) -
Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report
por: Yamasaki, Masahiro, et al.
Publicado: (2018) -
Pericardial Effusion With Tamponade in Lung Cancer Patients During Treatment With Nivolumab: A Report of Two Cases
por: Yamasaki, Masahiro, et al.
Publicado: (2019) -
Reply to Takimoto: Micronodular Pattern of Organizing Pneumonia or Hypersensitivity Pneumonia Induced by an Immune Checkpoint Inhibitor?
por: Yamasaki, Masahiro, et al.
Publicado: (2020)